PEG Ratio: 33.99
Is the PEG ratio high or low?
The PEG ratio of 33.99 is 101% above its 5-year average of 16.88, near the high end of its 5-year range (0.58–33.99).
WST PEG Ratio Chart
Reported annual fiscal-period values; no daily interpolation.
WST Average PEG Ratio Chart
WST Current vs Average PEG Ratio Chart
WST PEG Ratio Metrics
PEG RATIO
33.99
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
32.78
PEG RATIO AVG 5Y
16.88
PEG RATIO AVG 10Y
10.50
PEG RATIO AVG 15Y
2.68
PEG RATIO AVG 20Y
1.79
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+3.69%
CURRENT VS 5Y AVG
+101.30%
CURRENT VS 10Y AVG
+223.79%
CURRENT VS 15Y AVG
+1167.81%
CURRENT VS 20Y AVG
+1797.25%
WST Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 33.99 | N/A | 32.78 | 16.88 |
| Waters Corporation (WAT)vs › | $24.41B | 75.61 | 75.61 | 40.77 | 27.51 |
| Mettler-Toledo International Inc. (MTD)vs › | $25.54B | 8.96 | 5.67 | 4.53 | 3.90 |
| Quest Diagnostics Incorporated (DGX)vs › | $23.08B | 1.43 | 4.21 | 4.21 | 2.20 |
| BioNTech SE (BNTX)vs › | $23.07B | N/A | 0.23 | 0.12 | 0.12 |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 1.16 | 0.84 | 0.59 | 0.59 |
| Moderna, Inc. (MRNA)vs › | $26.69B | N/A | 0.18 | 0.14 | 0.14 |
| Incyte Corporation (INCY)vs › | $22.73B | 0.76 | 0.00 | 0.16 | 0.24 |
| DexCom, Inc. (DXCM)vs › | $27.07B | 0.67 | 19.51 | 10.66 | 8.56 |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 1.28 | 0.79 | 0.79 | 0.47 |
Growth-Adjusted Valuation
PEG Ratio
33.99
P/E Ratio
46.8
PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
PEG Ratio FAQ
- What is the PEG ratio for West Pharmaceutical Services, Inc. (WST)?
- The PEG ratio for WST stock is 33.99.
- Is West Pharmaceutical Services, Inc.'s PEG ratio high or low?
- The PEG ratio of 33.99 is 101% above its 5-year average of 16.88, near the high end of its 5-year range (0.58–33.99).
- What is the 3Y average PEG ratio for West Pharmaceutical Services, Inc. (WST)?
- The 3Y average PEG ratio for WST stock is 32.78.
- What is the 5Y average PEG ratio for West Pharmaceutical Services, Inc. (WST)?
- The 5Y average PEG ratio for WST stock is 16.88.
- What is the 10Y average PEG ratio for West Pharmaceutical Services, Inc. (WST)?
- The 10Y average PEG ratio for WST stock is 10.50.
- What is the 15Y average PEG ratio for West Pharmaceutical Services, Inc. (WST)?
- The 15Y average PEG ratio for WST stock is 2.68.
- What is the 20Y average PEG ratio for West Pharmaceutical Services, Inc. (WST)?
- The 20Y average PEG ratio for WST stock is 1.79.
WST PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-31 | 33.99 |
| 2023-12-31 | 31.57 |
| 2021-12-31 | 0.58 |
| 2020-12-31 | 1.40 |
| 2019-12-31 | 2.74 |
| 2018-12-31 | 0.94 |
| 2017-12-31 | 11.85 |
| 2016-12-31 | 0.91 |
| 2014-12-31 | 2.66 |
| 2013-12-31 | 0.86 |
| 2012-12-31 | 3.68 |
| 2011-12-31 | 1.19 |
| 2008-12-31 | 0.61 |
| 2007-12-31 | 6.58 |
| 2006-12-31 | 0.61 |
| 2005-12-31 | 0.53 |
| 2003-12-31 | 0.09 |
| 2001-12-31 | 0.16 |
| 1999-12-31 | 0.02 |
| 1997-12-31 | 0.07 |
Related Metrics
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green